Levosimendan protects against ischemia – reperfusion injury in the human heart muscle. A pilot study
The consequences of myocardial infarction (MI) are an increasing problem worldwide. Despite spectacular progress in the invasive treatment of ischemic heart disease, the ability to limit the ischemia-reperfusion (I/R) injury remains largely unrealized. Recent studies have shown that stimulation of o...
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado: |
Sciendo
2022-12-01
|
| Series: | Current Issues in Pharmacy and Medical Sciences |
| Subjects: | |
| Acceso en liña: | https://doi.org/10.2478/cipms-2022-0038 |